Resources for Industry
The National Cancer Institute (NCI) works closely with private sector partners, including the pharmaceutical and biotechnology industry in its efforts to develop approaches and technologies to prevent, diagnose, and treat cancer.
Small Business Innovation Research & Small Business Technology Transfer
The Small Business Innovation Research and Small Business Technology Transfer (SBIR) and Small Business Technology Transfer programs enable NCI to partner with small businesses to develop and commercialize new technologies and product and are a major source of early-stage technology financing for U.S. small businesses.
NCI Technology Transfer Center
The Technology Transfer Center makes it easy for industry and academia to interact and partner with NCI laboratories and scientists to support technology development activities.
Center for Cancer Research-Office of Science and Technology Resources
The Office of Science and Technology Resources (OSTR) identifies, evaluates and makes available new technologies and scientific resources to NCI's Center for Cancer Research (CCR) investigators through partnerships, collaborations, contracts and other technology transfer agreements with outside organizations, including the private sector.
CTEP Guidelines for Collaborations with Industry
Cancer Therapy Evaluation Program within NCI’s Division of Cancer Treatment and Diagnosis has model agreements, intellectual property policy, and industry relationship guidelines.
DCTD Resources for Industry Researchers
NCI’s Division of Cancer Treatment and Diagnosis has drug discovery and development, imaging, human tissue specimen, and clinical trials resources for researchers from the pharmaceutical and biotechnology industry.
Frederick National Laboratory for Cancer Research
The Partnership Development Office at the Frederick National Laboratory for Cancer Research facilitates collaboration with academia, life sciences companies, and non-profit research organizations.
The NExT program, a partnership between NCI’s Division of Cancer Treatment and Diagnosis and Center for Cancer Research, seeks to partner with small biotechnology and pharmaceutical companies and academia to facilitate translation of innovative scientific discoveries into new approaches for diagnosing and treating rare and refractory tumors.
Early Detection Research Network
The Early Detection Research Network, a program sponsored by the Division of Cancer Prevention, promotes collaboration among academic and industry leaders in molecular biology, molecular genetics, clinical oncology, computer science, public health and clinical application for early cancer detection.
PREVENT Cancer Preclinical Drug Development Program
The PREVENT program, sponsored by the Division of Cancer Prevention, is designed to bring new cancer prevention interventions and biomarkers through preclinical development towards clinical trials.